| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Infant, Premature, Diseases | 49 | 2022 | 63 | 11.520 |
Why?
|
| Infant, Premature | 80 | 2023 | 128 | 8.200 |
Why?
|
| Infant, Newborn | 167 | 2023 | 871 | 7.770 |
Why?
|
| Gestational Age | 59 | 2023 | 190 | 4.550 |
Why?
|
| Infant Mortality | 24 | 2023 | 57 | 3.940 |
Why?
|
| Infant, Extremely Low Birth Weight | 26 | 2023 | 28 | 3.700 |
Why?
|
| Retinopathy of Prematurity | 21 | 2023 | 25 | 3.520 |
Why?
|
| Infant, Very Low Birth Weight | 25 | 2022 | 44 | 3.360 |
Why?
|
| Infant | 66 | 2023 | 1014 | 3.350 |
Why?
|
| Hospital Mortality | 20 | 2022 | 183 | 2.750 |
Why?
|
| Premature Birth | 9 | 2022 | 71 | 2.610 |
Why?
|
| Bronchopulmonary Dysplasia | 16 | 2022 | 22 | 2.480 |
Why?
|
| Erythrocyte Transfusion | 12 | 2023 | 18 | 2.340 |
Why?
|
| Enterocolitis, Necrotizing | 15 | 2022 | 19 | 2.270 |
Why?
|
| Humans | 187 | 2023 | 34853 | 2.110 |
Why?
|
| Intensive Care Units, Neonatal | 15 | 2022 | 39 | 2.100 |
Why?
|
| Anemia, Neonatal | 5 | 2023 | 5 | 1.980 |
Why?
|
| Female | 137 | 2023 | 19873 | 1.970 |
Why?
|
| Intensive Care, Neonatal | 8 | 2021 | 12 | 1.820 |
Why?
|
| Ductus Arteriosus, Patent | 9 | 2023 | 13 | 1.680 |
Why?
|
| Male | 122 | 2023 | 18870 | 1.680 |
Why?
|
| Anemia | 4 | 2023 | 45 | 1.650 |
Why?
|
| Developmental Disabilities | 17 | 2021 | 59 | 1.490 |
Why?
|
| Sepsis | 10 | 2021 | 76 | 1.470 |
Why?
|
| Politics | 3 | 2019 | 35 | 1.470 |
Why?
|
| Pregnancy | 35 | 2023 | 1503 | 1.450 |
Why?
|
| Child Development | 13 | 2023 | 84 | 1.410 |
Why?
|
| Body Temperature | 3 | 2018 | 39 | 1.400 |
Why?
|
| Retrospective Studies | 46 | 2022 | 1961 | 1.360 |
Why?
|
| Birth Weight | 12 | 2023 | 93 | 1.340 |
Why?
|
| Hypoxia-Ischemia, Brain | 8 | 2022 | 42 | 1.320 |
Why?
|
| Hypothermia, Induced | 8 | 2022 | 26 | 1.230 |
Why?
|
| Adrenal Cortex Hormones | 10 | 2022 | 48 | 1.210 |
Why?
|
| Milk, Human | 5 | 2023 | 29 | 1.170 |
Why?
|
| Intracranial Hemorrhages | 7 | 2022 | 26 | 1.150 |
Why?
|
| Infant, Newborn, Diseases | 8 | 2021 | 18 | 1.110 |
Why?
|
| Withholding Treatment | 4 | 2020 | 29 | 1.100 |
Why?
|
| Hypothermia | 4 | 2022 | 14 | 1.080 |
Why?
|
| Critical Care | 2 | 2021 | 37 | 1.080 |
Why?
|
| Glucocorticoids | 5 | 2022 | 80 | 1.040 |
Why?
|
| Registries | 16 | 2022 | 330 | 1.020 |
Why?
|
| Neonatal Screening | 8 | 2020 | 26 | 1.010 |
Why?
|
| Delivery, Obstetric | 3 | 2015 | 38 | 0.990 |
Why?
|
| United States | 40 | 2023 | 3894 | 0.970 |
Why?
|
| Erythropoietin | 2 | 2023 | 37 | 0.960 |
Why?
|
| Risk Factors | 31 | 2021 | 3414 | 0.940 |
Why?
|
| Tocopherols | 2 | 2013 | 62 | 0.940 |
Why?
|
| Patient Discharge | 8 | 2023 | 92 | 0.930 |
Why?
|
| Prospective Studies | 28 | 2022 | 1353 | 0.920 |
Why?
|
| Practice Guidelines as Topic | 7 | 2021 | 187 | 0.910 |
Why?
|
| Resuscitation | 8 | 2020 | 17 | 0.910 |
Why?
|
| Parenteral Nutrition | 3 | 2021 | 11 | 0.870 |
Why?
|
| Blood Transfusion | 2 | 2023 | 26 | 0.870 |
Why?
|
| Social Sciences | 2 | 2018 | 4 | 0.850 |
Why?
|
| Respiratory Distress Syndrome, Newborn | 8 | 2021 | 19 | 0.840 |
Why?
|
| Fetal Growth Retardation | 1 | 2022 | 51 | 0.830 |
Why?
|
| Cohort Studies | 22 | 2023 | 1422 | 0.820 |
Why?
|
| Breast Feeding | 6 | 2023 | 105 | 0.810 |
Why?
|
| Survival Rate | 17 | 2021 | 310 | 0.800 |
Why?
|
| Prenatal Exposure Delayed Effects | 8 | 2020 | 155 | 0.780 |
Why?
|
| Culture | 2 | 2018 | 162 | 0.770 |
Why?
|
| Attitude | 2 | 2018 | 97 | 0.760 |
Why?
|
| Neonatology | 3 | 2016 | 7 | 0.740 |
Why?
|
| Family | 2 | 2018 | 162 | 0.730 |
Why?
|
| Vitamins | 3 | 2021 | 91 | 0.720 |
Why?
|
| Cause of Death | 5 | 2018 | 154 | 0.720 |
Why?
|
| Intestinal Perforation | 5 | 2022 | 10 | 0.710 |
Why?
|
| Oxygen Inhalation Therapy | 6 | 2022 | 13 | 0.700 |
Why?
|
| Brain | 10 | 2022 | 1268 | 0.690 |
Why?
|
| Leukomalacia, Periventricular | 7 | 2020 | 7 | 0.690 |
Why?
|
| Treatment Outcome | 19 | 2021 | 1349 | 0.680 |
Why?
|
| Chromatography, High Pressure Liquid | 5 | 2013 | 406 | 0.660 |
Why?
|
| Vitamin A | 2 | 2021 | 87 | 0.650 |
Why?
|
| Respiration, Artificial | 8 | 2022 | 37 | 0.650 |
Why?
|
| Pregnancy Outcome | 4 | 2020 | 90 | 0.640 |
Why?
|
| Morbidity | 9 | 2022 | 94 | 0.640 |
Why?
|
| Herb-Drug Interactions | 2 | 2007 | 4 | 0.620 |
Why?
|
| Hypericum | 2 | 2007 | 4 | 0.620 |
Why?
|
| Hematocrit | 5 | 2014 | 18 | 0.620 |
Why?
|
| Temporal Arteries | 1 | 2017 | 2 | 0.620 |
Why?
|
| Plant Preparations | 2 | 2007 | 21 | 0.610 |
Why?
|
| Prone Position | 1 | 2016 | 3 | 0.600 |
Why?
|
| Supine Position | 1 | 2016 | 4 | 0.600 |
Why?
|
| Follow-Up Studies | 20 | 2022 | 964 | 0.590 |
Why?
|
| Child | 15 | 2023 | 2875 | 0.590 |
Why?
|
| Environment | 1 | 2018 | 130 | 0.590 |
Why?
|
| Survivors | 3 | 2022 | 126 | 0.580 |
Why?
|
| Romania | 4 | 2017 | 6 | 0.540 |
Why?
|
| Continuous Positive Airway Pressure | 6 | 2021 | 15 | 0.540 |
Why?
|
| Pregnancy in Adolescence | 1 | 2015 | 33 | 0.540 |
Why?
|
| Energy Metabolism | 1 | 2016 | 160 | 0.530 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 3 | 2017 | 112 | 0.520 |
Why?
|
| Dehydration | 1 | 2014 | 21 | 0.520 |
Why?
|
| Ibuprofen | 3 | 2023 | 33 | 0.510 |
Why?
|
| Twins | 3 | 2019 | 16 | 0.510 |
Why?
|
| Logistic Models | 17 | 2020 | 894 | 0.510 |
Why?
|
| Indomethacin | 5 | 2023 | 24 | 0.510 |
Why?
|
| Erythrocyte Volume | 2 | 2013 | 4 | 0.510 |
Why?
|
| alpha-Tocopherol | 2 | 2013 | 25 | 0.500 |
Why?
|
| Vitamin E Deficiency | 1 | 2013 | 2 | 0.490 |
Why?
|
| Inositol | 4 | 2021 | 20 | 0.480 |
Why?
|
| Intubation, Intratracheal | 4 | 2021 | 22 | 0.480 |
Why?
|
| Length of Stay | 7 | 2018 | 184 | 0.480 |
Why?
|
| Oxygen | 7 | 2022 | 193 | 0.480 |
Why?
|
| Risk Assessment | 10 | 2020 | 727 | 0.470 |
Why?
|
| Life Support Care | 3 | 2020 | 8 | 0.470 |
Why?
|
| National Institute of Child Health and Human Development (U.S.) | 7 | 2023 | 7 | 0.460 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2021 | 233 | 0.450 |
Why?
|
| Aftercare | 2 | 2023 | 18 | 0.450 |
Why?
|
| Child, Preschool | 10 | 2022 | 1318 | 0.450 |
Why?
|
| Biomedical Research | 2 | 2016 | 371 | 0.450 |
Why?
|
| Language Disorders | 1 | 2012 | 5 | 0.430 |
Why?
|
| Prenatal Care | 7 | 2021 | 74 | 0.420 |
Why?
|
| Fetal Blood | 2 | 2014 | 47 | 0.420 |
Why?
|
| Adult | 24 | 2023 | 11034 | 0.420 |
Why?
|
| Attitude of Health Personnel | 1 | 2013 | 186 | 0.410 |
Why?
|
| Memory Disorders | 1 | 2012 | 65 | 0.410 |
Why?
|
| Sex Factors | 6 | 2018 | 859 | 0.410 |
Why?
|
| Anti-Bacterial Agents | 7 | 2021 | 355 | 0.410 |
Why?
|
| Fetal Viability | 3 | 2021 | 3 | 0.410 |
Why?
|
| Placental Circulation | 1 | 2011 | 1 | 0.400 |
Why?
|
| Age Factors | 7 | 2020 | 1007 | 0.400 |
Why?
|
| Bilirubin | 1 | 2010 | 17 | 0.390 |
Why?
|
| Interleukin-10 | 2 | 2010 | 69 | 0.390 |
Why?
|
| Stillbirth | 2 | 2023 | 7 | 0.390 |
Why?
|
| Parturition | 1 | 2010 | 22 | 0.380 |
Why?
|
| Calcitonin | 1 | 2010 | 5 | 0.380 |
Why?
|
| Receptors, IgG | 1 | 2010 | 48 | 0.370 |
Why?
|
| Rehabilitation, Vocational | 1 | 2010 | 1 | 0.370 |
Why?
|
| Time Factors | 12 | 2020 | 1681 | 0.370 |
Why?
|
| Cognition | 5 | 2020 | 373 | 0.370 |
Why?
|
| Visually Impaired Persons | 1 | 2010 | 6 | 0.370 |
Why?
|
| Blindness | 1 | 2010 | 16 | 0.370 |
Why?
|
| Protein Precursors | 1 | 2010 | 59 | 0.370 |
Why?
|
| Hemoglobins | 5 | 2023 | 101 | 0.360 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2021 | 638 | 0.350 |
Why?
|
| Neutrophils | 1 | 2010 | 124 | 0.350 |
Why?
|
| Cerebral Palsy | 5 | 2022 | 11 | 0.350 |
Why?
|
| Prognosis | 10 | 2022 | 707 | 0.350 |
Why?
|
| Employment | 1 | 2010 | 73 | 0.350 |
Why?
|
| Nervous System Diseases | 4 | 2014 | 66 | 0.350 |
Why?
|
| Internship and Residency | 1 | 2010 | 121 | 0.340 |
Why?
|
| Incidence | 12 | 2022 | 882 | 0.330 |
Why?
|
| Infant Equipment | 2 | 2018 | 2 | 0.330 |
Why?
|
| Incubators, Infant | 2 | 2018 | 3 | 0.330 |
Why?
|
| Cross-Cultural Comparison | 2 | 2018 | 100 | 0.320 |
Why?
|
| Cardiopulmonary Resuscitation | 2 | 2018 | 27 | 0.320 |
Why?
|
| Magnesium Sulfate | 2 | 2020 | 5 | 0.320 |
Why?
|
| Prednisolone | 1 | 2007 | 13 | 0.320 |
Why?
|
| Prednisone | 1 | 2007 | 26 | 0.320 |
Why?
|
| Streptococcal Infections | 2 | 2022 | 32 | 0.320 |
Why?
|
| Drug Administration Schedule | 4 | 2020 | 145 | 0.310 |
Why?
|
| Young Adult | 11 | 2022 | 4012 | 0.310 |
Why?
|
| Genotype | 3 | 2018 | 641 | 0.310 |
Why?
|
| Severity of Illness Index | 6 | 2020 | 608 | 0.310 |
Why?
|
| Patient Selection | 2 | 2021 | 154 | 0.300 |
Why?
|
| Enteral Nutrition | 2 | 2019 | 16 | 0.300 |
Why?
|
| Seizures | 2 | 2021 | 67 | 0.300 |
Why?
|
| Infant, Small for Gestational Age | 5 | 2018 | 17 | 0.300 |
Why?
|
| Early Termination of Clinical Trials | 2 | 2016 | 2 | 0.290 |
Why?
|
| Iowa | 5 | 2020 | 8 | 0.290 |
Why?
|
| Case-Control Studies | 8 | 2021 | 1056 | 0.290 |
Why?
|
| Escherichia coli Infections | 2 | 2020 | 39 | 0.280 |
Why?
|
| Infant Formula | 2 | 2023 | 13 | 0.280 |
Why?
|
| Decision Making | 2 | 2018 | 189 | 0.270 |
Why?
|
| Lactobacillus acidophilus | 1 | 2005 | 3 | 0.260 |
Why?
|
| Bifidobacterium | 1 | 2005 | 3 | 0.260 |
Why?
|
| Cerebral Hemorrhage | 3 | 2020 | 103 | 0.260 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2020 | 468 | 0.260 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 2 | 2018 | 58 | 0.260 |
Why?
|
| Vaccinia virus | 1 | 2004 | 10 | 0.250 |
Why?
|
| Probiotics | 1 | 2005 | 25 | 0.250 |
Why?
|
| Neuropsychological Tests | 4 | 2017 | 255 | 0.250 |
Why?
|
| Maternal Age | 4 | 2019 | 27 | 0.250 |
Why?
|
| Odds Ratio | 5 | 2020 | 517 | 0.250 |
Why?
|
| Socioeconomic Factors | 2 | 2018 | 1003 | 0.250 |
Why?
|
| Hydrocortisone | 2 | 2022 | 72 | 0.250 |
Why?
|
| Adolescent | 6 | 2019 | 5035 | 0.250 |
Why?
|
| Oximetry | 4 | 2021 | 11 | 0.250 |
Why?
|
| Down Syndrome | 3 | 2014 | 29 | 0.250 |
Why?
|
| Germany | 3 | 2019 | 21 | 0.240 |
Why?
|
| Pulmonary Surfactants | 5 | 2021 | 26 | 0.240 |
Why?
|
| Reticulocytes | 1 | 2023 | 9 | 0.240 |
Why?
|
| Viral Envelope Proteins | 1 | 2004 | 77 | 0.240 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2023 | 20 | 0.240 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2023 | 24 | 0.240 |
Why?
|
| Escherichia coli | 2 | 2020 | 436 | 0.230 |
Why?
|
| Chromosome Disorders | 2 | 2014 | 10 | 0.230 |
Why?
|
| Infant, Low Birth Weight | 3 | 2021 | 37 | 0.230 |
Why?
|
| Membrane Glycoproteins | 1 | 2004 | 197 | 0.230 |
Why?
|
| Parents | 2 | 2018 | 288 | 0.220 |
Why?
|
| Sex Characteristics | 2 | 2021 | 213 | 0.220 |
Why?
|
| Psychomotor Performance | 3 | 2014 | 126 | 0.220 |
Why?
|
| Steroids | 1 | 2022 | 43 | 0.220 |
Why?
|
| Energy Intake | 2 | 2021 | 160 | 0.210 |
Why?
|
| Insulin | 3 | 2023 | 224 | 0.210 |
Why?
|
| Rewarming | 1 | 2021 | 2 | 0.210 |
Why?
|
| Laparotomy | 1 | 2021 | 3 | 0.210 |
Why?
|
| Drainage | 1 | 2021 | 11 | 0.210 |
Why?
|
| Electrolytes | 1 | 2021 | 25 | 0.210 |
Why?
|
| Wechsler Scales | 2 | 2012 | 7 | 0.210 |
Why?
|
| Mothers | 2 | 2021 | 164 | 0.210 |
Why?
|
| Bottle Feeding | 2 | 2019 | 13 | 0.210 |
Why?
|
| Strabismus | 1 | 2021 | 17 | 0.210 |
Why?
|
| Bacteremia | 2 | 2012 | 31 | 0.200 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2019 | 56 | 0.200 |
Why?
|
| Water-Electrolyte Balance | 1 | 2021 | 17 | 0.200 |
Why?
|
| Skin Physiological Phenomena | 1 | 2021 | 11 | 0.200 |
Why?
|
| Vaccines, Attenuated | 1 | 2021 | 72 | 0.200 |
Why?
|
| Viral Vaccines | 1 | 2021 | 28 | 0.200 |
Why?
|
| Persistent Fetal Circulation Syndrome | 1 | 2020 | 1 | 0.190 |
Why?
|
| Educational Status | 3 | 2012 | 295 | 0.190 |
Why?
|
| Temperature | 5 | 2022 | 275 | 0.190 |
Why?
|
| Tissue Donors | 1 | 2021 | 43 | 0.190 |
Why?
|
| Cerebral Ventricles | 1 | 2020 | 23 | 0.190 |
Why?
|
| Predictive Value of Tests | 4 | 2020 | 424 | 0.190 |
Why?
|
| Mortality | 2 | 2020 | 150 | 0.190 |
Why?
|
| Glycoprotein Hormones, alpha Subunit | 1 | 2020 | 1 | 0.190 |
Why?
|
| Pituitary Hormones | 1 | 2020 | 3 | 0.190 |
Why?
|
| Refrigeration | 1 | 2020 | 4 | 0.190 |
Why?
|
| Gastrointestinal Tract | 1 | 2021 | 59 | 0.190 |
Why?
|
| Infant Behavior | 1 | 2020 | 4 | 0.190 |
Why?
|
| Food Analysis | 1 | 2020 | 30 | 0.180 |
Why?
|
| Motor Skills | 1 | 2020 | 25 | 0.180 |
Why?
|
| Language Development | 1 | 2020 | 18 | 0.180 |
Why?
|
| Dexamethasone | 1 | 2020 | 43 | 0.180 |
Why?
|
| Hormones | 1 | 2020 | 51 | 0.180 |
Why?
|
| Gastrostomy | 1 | 2019 | 7 | 0.180 |
Why?
|
| Diseases in Twins | 1 | 2019 | 6 | 0.180 |
Why?
|
| Flow Cytometry | 1 | 2021 | 392 | 0.180 |
Why?
|
| Heart | 1 | 2021 | 178 | 0.170 |
Why?
|
| Survival Analysis | 5 | 2015 | 322 | 0.170 |
Why?
|
| Personality | 1 | 2019 | 36 | 0.170 |
Why?
|
| Home Care Services | 1 | 2019 | 29 | 0.170 |
Why?
|
| Brain Injuries | 1 | 2020 | 104 | 0.170 |
Why?
|
| Impetigo | 1 | 2018 | 1 | 0.170 |
Why?
|
| Spouses | 1 | 2018 | 29 | 0.170 |
Why?
|
| Quinolones | 1 | 2018 | 7 | 0.170 |
Why?
|
| Kidney | 1 | 2021 | 322 | 0.170 |
Why?
|
| Aminopyridines | 1 | 2018 | 13 | 0.170 |
Why?
|
| Chorioamnionitis | 2 | 2018 | 6 | 0.160 |
Why?
|
| Double-Blind Method | 4 | 2022 | 269 | 0.160 |
Why?
|
| Resuscitation Orders | 1 | 2018 | 8 | 0.160 |
Why?
|
| Hydrocephalus | 1 | 2018 | 16 | 0.160 |
Why?
|
| Databases, Factual | 4 | 2023 | 288 | 0.160 |
Why?
|
| Cardiovascular Diseases | 2 | 2015 | 628 | 0.160 |
Why?
|
| Critical Illness | 2 | 2015 | 37 | 0.160 |
Why?
|
| Overweight | 1 | 2020 | 233 | 0.160 |
Why?
|
| Academic Medical Centers | 1 | 2018 | 54 | 0.160 |
Why?
|
| Streptococcus agalactiae | 2 | 2022 | 10 | 0.160 |
Why?
|
| Drug Utilization | 2 | 2017 | 29 | 0.160 |
Why?
|
| Axilla | 1 | 2017 | 8 | 0.150 |
Why?
|
| Research Design | 2 | 2016 | 292 | 0.150 |
Why?
|
| Weight Gain | 1 | 2018 | 128 | 0.150 |
Why?
|
| Thermometers | 1 | 2017 | 4 | 0.150 |
Why?
|
| Cytokines | 1 | 2021 | 569 | 0.150 |
Why?
|
| Rectum | 1 | 2017 | 22 | 0.150 |
Why?
|
| Trisomy | 2 | 2014 | 10 | 0.150 |
Why?
|
| Acidosis | 2 | 2014 | 49 | 0.150 |
Why?
|
| Calorimetry, Indirect | 1 | 2016 | 9 | 0.150 |
Why?
|
| Congenital Abnormalities | 2 | 2015 | 19 | 0.150 |
Why?
|
| Body Temperature Regulation | 1 | 2016 | 8 | 0.150 |
Why?
|
| Growth | 1 | 2016 | 12 | 0.150 |
Why?
|
| Cesarean Section | 4 | 2020 | 53 | 0.150 |
Why?
|
| Pregnancy, Multiple | 1 | 2016 | 6 | 0.150 |
Why?
|
| Clinical Trials Data Monitoring Committees | 1 | 2016 | 1 | 0.150 |
Why?
|
| Pregnancy in Diabetics | 1 | 2016 | 4 | 0.150 |
Why?
|
| Statistics as Topic | 1 | 2016 | 111 | 0.140 |
Why?
|
| Head | 1 | 2016 | 30 | 0.140 |
Why?
|
| Longitudinal Studies | 3 | 2019 | 841 | 0.140 |
Why?
|
| Perinatal Care | 1 | 2015 | 15 | 0.140 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2016 | 58 | 0.140 |
Why?
|
| Therapeutics | 1 | 2015 | 1 | 0.140 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 446 | 0.140 |
Why?
|
| Genome-Wide Association Study | 1 | 2017 | 271 | 0.130 |
Why?
|
| Perinatal Mortality | 1 | 2015 | 2 | 0.130 |
Why?
|
| Feeding Behavior | 1 | 2019 | 418 | 0.130 |
Why?
|
| Heart Defects, Congenital | 2 | 2013 | 61 | 0.130 |
Why?
|
| Reproducibility of Results | 2 | 2016 | 901 | 0.130 |
Why?
|
| Health Care Surveys | 2 | 2013 | 136 | 0.130 |
Why?
|
| Pharmacology, Clinical | 1 | 2014 | 1 | 0.130 |
Why?
|
| Clinical Trials as Topic | 1 | 2016 | 195 | 0.130 |
Why?
|
| Dietary Supplements | 2 | 2007 | 196 | 0.130 |
Why?
|
| Respiration Disorders | 1 | 2014 | 10 | 0.130 |
Why?
|
| Problem-Based Learning | 1 | 2014 | 32 | 0.130 |
Why?
|
| Tracheostomy | 1 | 2014 | 5 | 0.120 |
Why?
|
| Vitamin E | 2 | 2005 | 56 | 0.120 |
Why?
|
| Intelligence | 1 | 2014 | 12 | 0.120 |
Why?
|
| Education, Pharmacy | 1 | 2014 | 32 | 0.120 |
Why?
|
| Chromatography, Reverse-Phase | 1 | 2013 | 8 | 0.120 |
Why?
|
| Echoencephalography | 3 | 2015 | 4 | 0.120 |
Why?
|
| Pyrrolidinones | 1 | 2013 | 6 | 0.120 |
Why?
|
| Weight Loss | 1 | 2014 | 124 | 0.120 |
Why?
|
| Quality Control | 1 | 2013 | 35 | 0.120 |
Why?
|
| Age of Onset | 3 | 2021 | 98 | 0.120 |
Why?
|
| Students, Pharmacy | 1 | 2014 | 37 | 0.120 |
Why?
|
| Central Nervous System Diseases | 1 | 2014 | 27 | 0.120 |
Why?
|
| Sensitivity and Specificity | 2 | 2018 | 555 | 0.120 |
Why?
|
| Professional-Family Relations | 1 | 2013 | 8 | 0.120 |
Why?
|
| Limit of Detection | 1 | 2013 | 56 | 0.120 |
Why?
|
| Attitude to Death | 1 | 2013 | 20 | 0.120 |
Why?
|
| Hospitals, University | 1 | 2013 | 38 | 0.120 |
Why?
|
| Solvents | 1 | 2013 | 93 | 0.120 |
Why?
|
| Hypotension | 1 | 2013 | 21 | 0.120 |
Why?
|
| Hemangioma | 1 | 2013 | 7 | 0.120 |
Why?
|
| Treatment Failure | 3 | 2018 | 65 | 0.120 |
Why?
|
| Heart Diseases | 1 | 2014 | 99 | 0.120 |
Why?
|
| Diterpenes | 1 | 2013 | 83 | 0.110 |
Why?
|
| Informed Consent | 1 | 2013 | 30 | 0.110 |
Why?
|
| Growth Disorders | 1 | 2013 | 22 | 0.110 |
Why?
|
| Curcumin | 1 | 2013 | 66 | 0.110 |
Why?
|
| Blood Pressure | 2 | 2015 | 613 | 0.110 |
Why?
|
| Canada | 3 | 2019 | 121 | 0.110 |
Why?
|
| Bayes Theorem | 3 | 2017 | 91 | 0.110 |
Why?
|
| Term Birth | 3 | 2018 | 9 | 0.110 |
Why?
|
| Methicillin | 1 | 2012 | 5 | 0.110 |
Why?
|
| Meningitis | 1 | 2012 | 8 | 0.110 |
Why?
|
| Language Tests | 1 | 2012 | 8 | 0.110 |
Why?
|
| Risk | 3 | 2013 | 256 | 0.110 |
Why?
|
| Terminology as Topic | 1 | 2012 | 32 | 0.110 |
Why?
|
| Communication | 1 | 2013 | 170 | 0.100 |
Why?
|
| Short Bowel Syndrome | 1 | 2011 | 2 | 0.100 |
Why?
|
| Nervous System | 1 | 2011 | 29 | 0.100 |
Why?
|
| Infant Nutritional Physiological Phenomena | 2 | 2023 | 35 | 0.100 |
Why?
|
| Triplets | 1 | 2011 | 4 | 0.100 |
Why?
|
| Multivariate Analysis | 3 | 2019 | 570 | 0.100 |
Why?
|
| Staphylococcal Infections | 1 | 2012 | 64 | 0.100 |
Why?
|
| Testosterone | 2 | 2023 | 181 | 0.100 |
Why?
|
| Workload | 1 | 2010 | 22 | 0.100 |
Why?
|
| New York | 1 | 2010 | 69 | 0.100 |
Why?
|
| Antifungal Agents | 1 | 2012 | 147 | 0.090 |
Why?
|
| Calcitonin Gene-Related Peptide | 1 | 2010 | 11 | 0.090 |
Why?
|
| Comorbidity | 2 | 2019 | 606 | 0.090 |
Why?
|
| Competitive Behavior | 1 | 2010 | 11 | 0.090 |
Why?
|
| Vocal Cord Paralysis | 1 | 2009 | 1 | 0.090 |
Why?
|
| Candidiasis | 1 | 2010 | 85 | 0.090 |
Why?
|
| Fever | 2 | 2022 | 57 | 0.090 |
Why?
|
| Memory | 1 | 2011 | 165 | 0.090 |
Why?
|
| Hearing Loss | 2 | 2020 | 11 | 0.090 |
Why?
|
| Analysis of Variance | 1 | 2011 | 528 | 0.090 |
Why?
|
| Animals | 6 | 2021 | 14307 | 0.090 |
Why?
|
| Poisson Distribution | 3 | 2014 | 39 | 0.090 |
Why?
|
| High-Frequency Ventilation | 1 | 2008 | 2 | 0.080 |
Why?
|
| Vision Disorders | 2 | 2020 | 59 | 0.080 |
Why?
|
| ATP-Binding Cassette Transporters | 2 | 2021 | 82 | 0.080 |
Why?
|
| Delivery Rooms | 2 | 2018 | 4 | 0.080 |
Why?
|
| Infusions, Intravenous | 3 | 2016 | 48 | 0.080 |
Why?
|
| Constriction | 1 | 2008 | 2 | 0.080 |
Why?
|
| Injections, Intramuscular | 2 | 2021 | 20 | 0.080 |
Why?
|
| Umbilical Cord | 1 | 2008 | 13 | 0.080 |
Why?
|
| Nicotinic Acids | 1 | 2008 | 11 | 0.080 |
Why?
|
| Carbon Dioxide | 1 | 2008 | 78 | 0.080 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2007 | 22 | 0.080 |
Why?
|
| Biological Availability | 2 | 2021 | 84 | 0.080 |
Why?
|
| Middle Aged | 2 | 2013 | 9642 | 0.080 |
Why?
|
| Plants, Medicinal | 1 | 2007 | 54 | 0.080 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2007 | 82 | 0.080 |
Why?
|
| Medical Futility | 2 | 2016 | 8 | 0.070 |
Why?
|
| Reference Values | 3 | 2011 | 204 | 0.070 |
Why?
|
| Gene Frequency | 2 | 2021 | 155 | 0.070 |
Why?
|
| Antineoplastic Agents | 1 | 2013 | 756 | 0.070 |
Why?
|
| Brain Damage, Chronic | 1 | 2005 | 5 | 0.070 |
Why?
|
| Apnea | 1 | 2005 | 6 | 0.070 |
Why?
|
| Cognition Disorders | 2 | 2020 | 233 | 0.070 |
Why?
|
| Baths | 1 | 2005 | 1 | 0.070 |
Why?
|
| Immersion | 1 | 2005 | 1 | 0.070 |
Why?
|
| Blood Donors | 1 | 2005 | 17 | 0.070 |
Why?
|
| Ligation | 2 | 2018 | 9 | 0.070 |
Why?
|
| Monitoring, Physiologic | 1 | 2005 | 35 | 0.070 |
Why?
|
| Methamphetamine | 1 | 2007 | 155 | 0.060 |
Why?
|
| Smallpox Vaccine | 1 | 2004 | 2 | 0.060 |
Why?
|
| Bioterrorism | 1 | 2004 | 18 | 0.060 |
Why?
|
| Immunoglobulins | 1 | 2004 | 36 | 0.060 |
Why?
|
| Neutralization Tests | 1 | 2004 | 53 | 0.060 |
Why?
|
| Mutagenesis | 1 | 2004 | 87 | 0.060 |
Why?
|
| Algorithms | 2 | 2020 | 435 | 0.060 |
Why?
|
| Linear Models | 2 | 2015 | 253 | 0.060 |
Why?
|
| Aged, 80 and over | 1 | 2010 | 2333 | 0.060 |
Why?
|
| Regression Analysis | 2 | 2016 | 429 | 0.060 |
Why?
|
| Albumins | 1 | 2023 | 24 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 13 | 2 | 2014 | 10 | 0.060 |
Why?
|
| Alabama | 1 | 2023 | 46 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 18 | 2 | 2014 | 12 | 0.060 |
Why?
|
| Ferritins | 1 | 2023 | 54 | 0.060 |
Why?
|
| Skin Care | 1 | 2022 | 2 | 0.060 |
Why?
|
| Confidence Intervals | 2 | 2014 | 151 | 0.060 |
Why?
|
| Antibodies, Monoclonal | 1 | 2004 | 282 | 0.060 |
Why?
|
| Antibodies, Viral | 1 | 2004 | 252 | 0.050 |
Why?
|
| Asphyxia Neonatorum | 1 | 2021 | 5 | 0.050 |
Why?
|
| Cerebrovascular Circulation | 1 | 2022 | 71 | 0.050 |
Why?
|
| Iron | 1 | 2023 | 204 | 0.050 |
Why?
|
| Ebola Vaccines | 1 | 2021 | 8 | 0.050 |
Why?
|
| Metabolic Clearance Rate | 1 | 2021 | 22 | 0.050 |
Why?
|
| Luteinizing Hormone | 1 | 2021 | 62 | 0.050 |
Why?
|
| Vero Cells | 1 | 2021 | 90 | 0.050 |
Why?
|
| Chi-Square Distribution | 2 | 2012 | 213 | 0.050 |
Why?
|
| Microsomes | 1 | 2021 | 52 | 0.050 |
Why?
|
| Vaccines, Synthetic | 1 | 2021 | 72 | 0.050 |
Why?
|
| Body Weight | 2 | 2018 | 404 | 0.050 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2021 | 41 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2021 | 196 | 0.050 |
Why?
|
| Virion | 1 | 2021 | 67 | 0.050 |
Why?
|
| Electroencephalography | 1 | 2021 | 108 | 0.050 |
Why?
|
| Ventriculoperitoneal Shunt | 1 | 2020 | 2 | 0.050 |
Why?
|
| Dilatation, Pathologic | 1 | 2020 | 9 | 0.050 |
Why?
|
| Sex Distribution | 1 | 2021 | 212 | 0.050 |
Why?
|
| Vermont | 1 | 2020 | 33 | 0.050 |
Why?
|
| Biological Transport | 1 | 2021 | 175 | 0.050 |
Why?
|
| Hemodynamics | 1 | 2020 | 86 | 0.050 |
Why?
|
| Demography | 1 | 2020 | 167 | 0.050 |
Why?
|
| Alleles | 1 | 2021 | 284 | 0.050 |
Why?
|
| Feeding Methods | 1 | 2019 | 3 | 0.050 |
Why?
|
| Disease Models, Animal | 1 | 2005 | 1300 | 0.050 |
Why?
|
| Twins, Dizygotic | 1 | 2019 | 8 | 0.040 |
Why?
|
| Twins, Monozygotic | 1 | 2019 | 8 | 0.040 |
Why?
|
| Progesterone | 1 | 2020 | 117 | 0.040 |
Why?
|
| Genetics, Behavioral | 1 | 2019 | 2 | 0.040 |
Why?
|
| Propensity Score | 1 | 2019 | 40 | 0.040 |
Why?
|
| Retreatment | 1 | 2018 | 8 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2018 | 12 | 0.040 |
Why?
|
| Administration, Topical | 1 | 2018 | 39 | 0.040 |
Why?
|
| Laser Coagulation | 1 | 2018 | 5 | 0.040 |
Why?
|
| Leptin | 1 | 2020 | 115 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2016 | 984 | 0.040 |
Why?
|
| Aged | 1 | 2010 | 6448 | 0.040 |
Why?
|
| Recurrence | 1 | 2018 | 125 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2018 | 142 | 0.040 |
Why?
|
| Self Efficacy | 1 | 2019 | 173 | 0.040 |
Why?
|
| Patient Admission | 1 | 2018 | 40 | 0.040 |
Why?
|
| Ultrasonography | 1 | 2018 | 115 | 0.040 |
Why?
|
| Staphylococcus aureus | 1 | 2018 | 80 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2018 | 157 | 0.040 |
Why?
|
| GTPase-Activating Proteins | 1 | 2017 | 26 | 0.040 |
Why?
|
| Microfilament Proteins | 1 | 2017 | 64 | 0.040 |
Why?
|
| Endopeptidases | 1 | 2017 | 58 | 0.040 |
Why?
|
| Ion Channels | 1 | 2017 | 69 | 0.040 |
Why?
|
| Universities | 1 | 2020 | 363 | 0.040 |
Why?
|
| Body Mass Index | 1 | 2020 | 775 | 0.040 |
Why?
|
| Forkhead Transcription Factors | 1 | 2017 | 74 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 2016 | 34 | 0.040 |
Why?
|
| Disease Progression | 1 | 2018 | 580 | 0.040 |
Why?
|
| Pregnancy Complications | 1 | 2017 | 132 | 0.040 |
Why?
|
| Organ Size | 1 | 2016 | 148 | 0.030 |
Why?
|
| Data Interpretation, Statistical | 1 | 2016 | 111 | 0.030 |
Why?
|
| Retina | 1 | 2018 | 255 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2017 | 180 | 0.030 |
Why?
|
| Health Services Needs and Demand | 1 | 2016 | 143 | 0.030 |
Why?
|
| Models, Biological | 1 | 2018 | 642 | 0.030 |
Why?
|
| Anesthesia | 1 | 2014 | 14 | 0.030 |
Why?
|
| Hemorrhage | 1 | 2014 | 46 | 0.030 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2014 | 33 | 0.030 |
Why?
|
| Prevalence | 1 | 2019 | 1425 | 0.030 |
Why?
|
| Thrombosis | 1 | 2014 | 61 | 0.030 |
Why?
|
| Acute Disease | 1 | 2014 | 141 | 0.030 |
Why?
|
| Educational Measurement | 1 | 2014 | 80 | 0.030 |
Why?
|
| Child Behavior Disorders | 1 | 2014 | 30 | 0.030 |
Why?
|
| Polysorbates | 1 | 2013 | 10 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2015 | 206 | 0.030 |
Why?
|
| Placebos | 1 | 2013 | 38 | 0.030 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2013 | 65 | 0.030 |
Why?
|
| Rats | 2 | 2013 | 3261 | 0.030 |
Why?
|
| Solubility | 1 | 2013 | 115 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 2013 | 30 | 0.030 |
Why?
|
| Hungary | 1 | 2013 | 9 | 0.030 |
Why?
|
| Polyethylene Glycols | 1 | 2013 | 80 | 0.030 |
Why?
|
| Multiple Birth Offspring | 1 | 2013 | 1 | 0.030 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2014 | 342 | 0.030 |
Why?
|
| Chromosome Aberrations | 1 | 2013 | 56 | 0.030 |
Why?
|
| Belgium | 1 | 2012 | 4 | 0.030 |
Why?
|
| Argentina | 1 | 2012 | 11 | 0.030 |
Why?
|
| Netherlands | 1 | 2012 | 9 | 0.030 |
Why?
|
| Hematinics | 1 | 2012 | 6 | 0.030 |
Why?
|
| Colombia | 1 | 2012 | 19 | 0.030 |
Why?
|
| Italy | 1 | 2012 | 22 | 0.030 |
Why?
|
| Spain | 1 | 2012 | 33 | 0.030 |
Why?
|
| Erythrocyte Indices | 1 | 2012 | 13 | 0.030 |
Why?
|
| Curriculum | 1 | 2014 | 237 | 0.030 |
Why?
|
| Psychomotor Disorders | 1 | 2011 | 7 | 0.030 |
Why?
|
| Neovascularization, Pathologic | 1 | 2013 | 122 | 0.030 |
Why?
|
| Pregnancy Trimester, Second | 1 | 2011 | 16 | 0.030 |
Why?
|
| Blood-Borne Pathogens | 1 | 2011 | 7 | 0.030 |
Why?
|
| Japan | 1 | 2012 | 296 | 0.030 |
Why?
|
| Ethanol | 1 | 2013 | 188 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2020 | 1802 | 0.020 |
Why?
|
| Cardiac Output | 1 | 2010 | 19 | 0.020 |
Why?
|
| Group II Phospholipases A2 | 1 | 2010 | 3 | 0.020 |
Why?
|
| Toll-Like Receptor 5 | 1 | 2010 | 6 | 0.020 |
Why?
|
| Catheter-Related Infections | 1 | 2010 | 11 | 0.020 |
Why?
|
| Primary Prevention | 1 | 2011 | 57 | 0.020 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2010 | 25 | 0.020 |
Why?
|
| Apgar Score | 1 | 2010 | 5 | 0.020 |
Why?
|
| Intention to Treat Analysis | 1 | 2010 | 11 | 0.020 |
Why?
|
| Oxygen Consumption | 1 | 2010 | 98 | 0.020 |
Why?
|
| Principal Component Analysis | 1 | 2010 | 79 | 0.020 |
Why?
|
| Sutures | 1 | 2009 | 2 | 0.020 |
Why?
|
| Iatrogenic Disease | 1 | 2009 | 7 | 0.020 |
Why?
|
| Laryngoscopy | 1 | 2009 | 6 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2010 | 423 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2013 | 1534 | 0.020 |
Why?
|
| Reference Standards | 1 | 2008 | 52 | 0.020 |
Why?
|
| Phenotype | 1 | 2010 | 650 | 0.020 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 2008 | 94 | 0.020 |
Why?
|
| Drug Stability | 1 | 2008 | 110 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2010 | 528 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2013 | 2561 | 0.020 |
Why?
|
| Birth Injuries | 1 | 2005 | 9 | 0.020 |
Why?
|
| Hospitals, Teaching | 1 | 2005 | 24 | 0.020 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2005 | 16 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2005 | 82 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2004 | 58 | 0.020 |
Why?
|